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Abstract
Many infants have some form of gastroesophageal reflux (GER) characterized by
occasional spitting up with burps. Symptomatic reflux called gastroesophageal reflux disease
(GERD) affects infants and causes a variety of symptoms and observable events. The diagnosis
of GER or GERD appears to be increasing in the infant population including healthy newborns
and those infants hospitalized for a variety of reasons. The purpose of this systematic review is
to identify evidence-based practice guidelines for the treatment of GERD, including
pharmacologic and non-pharmacologic interventions in the neonatal/infant population.

The

results of this study show that conservative therapies should be used initially in the treatment of
GERD. If conservative therapies are unsuccessful, interventions including feedings can be used
prior to the addition of pharmaceutical therapies.
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Chapter 1. Introduction

Introduction to the Problem
Gastroesophageal reflux (GER) refers to the presence of gastric contents in the
esophagus proximal to the stomach (Mohan & Soni, 2002). Symptomatic reflux called
gastroesophageal reflux disease (GERD) includes infants who have a variety of symptoms and
observable events including vomiting more than two times per day, desaturations, arching,
drooling, recurrent pneumonias, stridor, recurrent coughs, irritability with feeding, apnea, and
bradycardia (Mohan & Soni, 2002). GERD may be associated with significant sequelae
including poor weight gain and chronic respiratory problems (Mohan & Soni, 2002). The
reported incidence of GER in preterm infants varies and ranges from 22% up to 85% Tipnis &
Tipnis, 2009). The diagnosis of GER or GERD appears to be increasing in the infant
population including healthy newborns and those infants hospitalized for a variety of reasons.
Many of those hospitalized children are discharged home on some type of reflux medication
(Orenstein & Hassall, 2007).
While evidence suggests that GER is common in most infants and that the incidence of
GER decreases with increasing gestational age, there is a variety of treatment measures used
in the neonatal intensive care unit (NICU) often without the diagnosis of GERD. These
treatments are not without risks and side effects. While some treatments are as benign as
elevating the head of an infant’s bed to prevent reflux, others include medications that have
been shown to increase the risk of other illnesses including acute gastroenteritis and
pneumonia (Canani, et al, 2006).
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Background to the Study
Diagnosis of gastroesophageal reflux (GER) or gastroesophageal reflux disease
(GERD) is sometimes difficult due to the controversy in diagnostic indicators. For example,
the esophageal pH probe detects reflux of gastric contents by placing a pH probe into the
lower third of the esophagus via nasal passage. The test measures the level of acidity of the
reflux contents in the esophagus. This test can last up to 24 hours, and incorrect probe
placement can produce inaccurate results. In addition, milk can act as a buffer to acidity after
feedings which makes acid detection difficult (Martin & Hibbs, 2009). Intraluminal
impedance, also known as multiple intraluminal impedance (MII), uses a catheter similar to a
pH probe and measures the impedance from multiple intraluminal sensors. The detection of
GER is based on changes in electrical resistance to current flow between electrodes. This is
an emerging technology that may be better able to detect reflux (Martin & Hibbs, 2009).
Upper gastrointestinal studies with small bowel follow through can be used to detect
GER, but these also have limitations. They require the use of barium which some infants
have trouble tolerating. In addition, these studies capture a moment in time rather than a
period over time. Unless the infant has an episode of reflux during this test, it will not be
detected (Martin & Hibbs, 2009).
In the Neonatal Intensive Care Unit (NICU), gastroesophageal reflux is commonly
reported by the nursing staff based on observable behaviors by infants including arching,
irritability, desaturations, apnea, and bradycardia. Many infants are placed on a variety of
pharmacologic agents to treat reflux, often without actual confirmed diagnosis of GERD.
Pharmacologic therapies consist of acid suppression agents, such as H2 receptor antagonists,

3

proton pump inhibitors, and prokinetic agents which improve gastric emptying. A common
drug used to treat GERD is ranitidine, an H2 receptor antagonist, but its efficacy in the
treatment of GERD in infants has not been demonstrated (Martin & Hibbs, 2009).
Omeprazole and lansoprazole, both proton pump inhibitors, are used frequently in the
treatment of GERD because of their acid reducing capabilities. There are concerns with using
acid suppression agents because of the risks of both necrotizing enterocolitis and altered
gastric colonizations (Martin & Hibbs, 2009).
Metoclopramide, a prokinetic agent, increases gastric emptying to decrease the amount
of contents in the stomach. This drug is indeed used frequently in the pediatric population.
However, the North American Society of Pediatric Gastroenterology, Hepatology, and
Nutrition does not support its use in the pediatric population because there is limited clinical
evidence of its efficacy (Vandenplas, et al, 2009).
Statement of the Problem
Gastroesophageal reflux disease (GERD) treatment is not standardized. There are no
clear guidelines to determine the use of pharmacologic or non-pharmacologic therapies
depending on severity of disease. In addition, partially due to the controversies with
diagnostic indicators, follow-up to determine effectiveness of the treatment used is
inconsistent.
Purpose of the Study
The purpose of this systematic review is to identify evidence-based practice
guidelines for the treatment of GERD, including pharmacologic and non-pharmacologic
interventions in the neonatal/infant population. In addition, treatment efficacy of
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pharmacologic and non-pharmacologic modalities will be addressed.
Formal Research Question
This research addresses the question: what are the best practices in the treatment of
gastroesophageal reflux disease in the neonatal/infant population?
Answering the above question may help practitioners to better understand the
treatment regimens associated with GERD. Evidence-based practice guidelines have the
potential to decrease the usage of pharmacologic agents that may affect long term outcomes
for infants, decrease side effects from their usage, and decrease costs to patients and families.
Significance of the Study
The diagnosis and treatment of GERD varies greatly among practitioners and often the
treatment comes without an actual diagnosis. In a recent study, Khoshoo, et al. (2009),
showed that 42 of 44 infants were on antireflux medications with only 8 of these infants
showing abnormal acid reflux on a pH probe study. The costs associated with the treatment
of GERD, including the diagnosis and pharmacologic agents, continue to increase. A
systematic review of available literature regarding neonates and infants with gastroesophageal
reflux will help to identify best practices for the treatment of GERD in this population. This
is important to healthcare administrators as some treatments may not be necessary or are used
with an increased risk of additional illnesses. In addition, since the research shows that
GERD may resolve over time (Suwandhi, et al, 2006), there is potential to use fewer
pharmacologic agents. This has the potential to significantly decrease costs to families and
decrease lost charges/reimbursements to hospitals. Attempts to standardize the treatment of
GERD can improve the quality of care in the NICU and increase patient safety.
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Definition of Terms
Gastroesophageal reflux (GER) refers to the presence of gastric contents in the esophagus
proximal to the stomach (Mohan & Soni, 2002).
Gastroesophageal reflux disease (GERD) is symptomatic GER and includes a variety of
symptoms and observable events (Mohan & Soni, 2002).
Neonates are babies from birth to 4 weeks old.
Infants are babies from one month to 1 year old.
Organization of the Remainder of the Paper
The following chapters will address the purpose, search strategy, levels of research, and
grading of studies. Papers that met the inclusion criteria are summarized and are reported in the
results section. The review provides suggestions for evidence-based guidelines for the treatment
of GERD.
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Chapter 2. Methodology
Purpose/Question
Gastroesophageal reflux disease (GERD) is treated frequently in the neonatal/infant
population. This is often done without confirmatory diagnosis and without evaluation of efficacy.
Some medications commonly prescribed for treatment are associated with side effects. In addition,
these medications can be expensive, creating a burden for families. The question addressed by this
project is: what are the best practices in the treatment of gastroesophageal reflux disease in the

neonatal/infant population?
Research Methodology
A systematic review of the literature was conducted for this study. Because there are not
currently evidence-based practice guidelines for the treatment of gastroesophageal reflux disease,
an analysis of the data is warranted. Systematic reviews are the cornerstone of evidence-based
practice and, if performed in a structured way, are replicable. The Cochrane Consumer Network
defines a systematic review as a study that summarizes available healthcare studies to provide a
higher level evidence to increase the effectiveness of healthcare interventions (Cochrane Consumer
Network, n.d.).

Search Strategy
The following databases were searched for relevant articles: PubMed, CINAHL,
MEDLINE, EMBASE, and the Cochrane Library. The following search terms were used in the
search: gastroesophageal reflux, gastro-esophageal reflux, gastro-oesophageal reflux, drug
therapy, diet therapy, and therapy. Only full text articles available through the Regis Library and
The Children’s Hospital Library were reviewed.
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Inclusion Criteria
1.

Studies that address neonates and infants (babies from birth to 23 months) and
preterm infants (those born before 37 weeks post conceptual age);

2.

Studies that address treatments for gastroesophageal reflux;

3.

Studies that include children up to 5 years old;

Exclusion Criteria
1.

Studies published prior to 2004;

2.

Studies not published in English;

3.

Studies that did not address gastroesophageal reflux as the main subject of the article;

4.

Studies that address gastroesophageal reflux as a co-morbidity;

5.

Studies that focus treatments on adults;

6.

Studies that focus on surgical interventions as a form of treatment;

7.

Studies that address subjects that have already had a surgical intervention for
gastroesophageal reflux.

Grading of Studies
Studies were assessed using the Level of Evidence Rating System for evaluation from
Stetler, et al, (1998). The levels are summarized below:
Levels of Evidence:


Level I:

Meta-analysis or systematic review of multiple controlled studies or
clinical trials



Level II:

Individual experimental studies with randomization



Level III:

Quasi-experimental studies such as nonrandomized controlled singleGroup, pre-post, cohort, time series, or matched case-controlled studies
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Level IV:

Nonexperimental studies, such as comparative and correlational
descriptive research as well as qualitative studies



Level V:

Program evaluation, research utilization, quality improvement projects,
case reports



Level VI:

Opinions of respected authorities; or the opinions of expert committee,
including their interpretation of non-research based information.

Once each study is classified by level, grades will be assigned based on the following criteria:


Grade A: Consistent level I studies



Grade B: Consistent level II or III studies or extrapolations from level 1 studies



Grade C: Level IV studies or extrapolations from level 2 or 3 studies



Grade D: Level V or VI evidence or troublingly inconsistent or inconclusive studies of
any level

Grade C and D studies will not be used in recommendations.

Sample Size
Sample size was determined by the available data in the established published time
frame. Saturation of the data was reached within the review articles. Eighty-six of the original
442 articles met the inclusion criteria and were used in the study.
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Chapter 3: Results
The initial search in PubMed which includes MEDLINE, EMBASE, and the Cochrane
Database yielded 424 results. Of those 424 articles, 78 were duplicated. Two hundred and sixty
one articles were removed due to the defined inclusion/exclusion criteria. The search of the
CINAHL database yielded 18 articles. Twelve of those articles did not meet the inclusion
criteria, four were duplicates. In total, 86 articles met the inclusion criteria and were assigned a
research level according to the Stetler, et al, (1998) levels of evidence. This system assigns a
level I rating to systematic reviews or meta-analysis and level II to individual experimental
studies with randomization. This system assigns a level III rating to quasi-experimental studies
such as nonrandomized controlled single-group, pre-post, cohort, time series, or matched casecontrolled studies. A second reader was used to confirm levels of evidence. The results of this
study are shown in Table I.
Much of the data in the systematic review articles were duplicated. Other articles
recommended a tiered approach to care beginning with conservative therapies and progressing to
more aggressive therapies if symptoms of gastroesophageal reflux continued. Systematic
reviews dealt with one intervention or treatment that may or may not have been recommended.
The conservative therapies or approaches to the treatment of gastroesophageal reflux in
neonates and infants found in the articles reviewed are summarized below:


Parental reassurance is the easiest, least invasive treatment for infant regurgitation as
symptoms usually decrease and disappear over time (Michail, 2007).



Prone or left-lateral positioning after feedings can reduce GERD in preterm infants but
cannot be used without cardiac monitoring because of the risk of SIDS (Corvaglia, et al,
(2007).
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Faster gastric emptying can be seen with less liquid reflux and feeding on right side
followed by change to left side after one hour (Van Wijk, et al, (2007).
If the above initial conservative therapies are not effective in the treatment of GERD, the

next approach identified in the articles is to use therapies related to a change in the feeding
process. Effective feeding strategies are listed below:


Small, slow, and more frequent feedings (with frequent burping) in a relaxed
environment are helpful to infants with delayed gastric emptying (Brodsky & Carr,
2006).



Eliminating exposure to cow’s milk (Vandenplas, et al, 2005).



Thickened feedings can reduce regurgitation events but commercially available products
may be better than additives because of the balanced nutrition in commercial products
(Vandenplas, et al, 2005).



Cornstarch can be used to thicken formula (Xinias, et al, 2005).



Cereal thickened formula (rice or oatmeal) can be used to reduce the frequency of
regurgitation (Chao & Vandenplas, 2007).



Hypoallergenic formula is supported in infants with recurrent emesis (Suwandhi, et al,
2006).
If initial conservative therapies are unsuccessful in relieving symptoms of

gastroesophageal reflux, some alterations in feedings have been shown to help. Brodsky & Carr
(2006) identified that small, slow, and frequent feedings are helpful to infants with delayed
gastric emptying. Vandenplas, et al, (2005) recommend the elimination of exposure to cow’s
milk as it may be efficacious for the reduction of symptoms of reflux.
There is a large amount of data both for and against the use of thickened feedings to
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reduce the symptoms of GERD. In a study by Chao & Vandenplas (2007), cornstarch-thickened
formula decreased the frequency of regurgitation and accelerated gastric emptying when
compared to a more concentrated (125%) formula. Chao & Vandenplas, in another study, also
showed that cereal-thickened formula is significantly more efficacious than positioning therapy
in decreasing the frequency of regurgitation (Chao & Vandenplas, 2007). Xinias, et al, showed
that a formula thickened with a specifically treated cornstarch reduced oesophageal reflux acid
exposure and reduces the frequency of clinical symptoms (Xinias, et al, 2005). Smaller volume
feeds thickened with rice cereal can alleviate symptoms of GERD but feeds thickened with
oatmeal can have the same results with less difficulty in defecation (Mascarenhas, et al, 2005).
There are some studies looking at the effect of locust bean gum on gastroesophageal
reflux. Miyazawa, et al (2007) showed a significant decrease in the number of regurgitation
episodes with locust bean gum-thickened formula, although this study had a very small sample
size and was non-randomized. In a randomized trial with two different concentrations of locust
bean gum-thickened formulas, there was a decrease in the number of regurgitation episodes
(Miyazawa, et al 2004). Although this may be important data, locust bean gum thickened
formulas are not currently available in the United States. A study in 2007 showed that prethickened AR (anti-regurgitation) formulas showed that this formula is more effective in
reducing the reflux index when GERD is more severe (Moukarzel, et al, 2007). Using a
commercially available pre-thickened formula may be best because of nutritional concerns.
Pharmacotherapy can be useful in the treatment of gastroesophageal reflux disease
although it should not be used as a first step in the treatment of reflux symptoms (Guimaraes, et
al (2006). Effective medications are listed below:
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Gaviscon Infant can be used as it increases the viscosity of feeds and reduces reflux (Del
Buono, et al, 2005).



Ranitidine, an H2 receptor antagonist, is successful in reducing gastric acidity, but long
term gastric acid inhibitors can have sequelae (Tighe, et al, 2010).



Omeprazole, a proton pump inhibitor, can only be limitedly recommended as it is not
well studied in neonates and infants (Bishop, et al, 2007).



Lansoprazole, a proton pump inhibitor, is well tolerated in neonates and infants but its
efficacy is only established in children older than 1 year (Springer, et al, 2008).



Esomeprazole, a proton pump inhibitor, does have acid suppressive effects in infants
older than 1 month at a dose of 1mg/kg; systemic exposure in preterm infants and
neonates at a dose of 0.5 mg/kg showed acid suppression but no effect on actual reflux
events. This medication is only approved for use in children 1 year and older (Omari, et
al, 2007).



Cimetidine, a prokinetic agent, can be recommended limitedly for reduced regurgitation
(Tighe, et al, 2010).
Gaviscon Infant, which acts as a feed thickener, prevents reflux by increasing the

viscosity of feeds. In a study by Del Buono, et al, (2005), patients given Gaviscon did show a
significant difference in reflux height in the esophagus when compared to placebo. It did not
show a difference in the number of reflux events (Del Buono, et al, 2005).
Tighe, et al, (2010) report that ranitidine, cimetidine, and famotidine have shown efficacy
superior to placebo for symptom relief and oesophageal healing in many clinical trials (Tighe, et
al, 2010). Omeprazole has not been extensively studied in children. In a small study in children
under 2 years, Bishop, et al, using pH studies to determine effectiveness, found the treatment
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effective, with no serious complications or side effects. The sample size was very small.
Lansoprazole is well studied for use. In a randomized, controlled trial in infants older than 3
months, the study group showed significant improvement in a shorter period of time when
compared to the control group (Khoshoo and Dhume, 2008). Springer, et al, were able to show
an increase in the percentage of time that intragastric pH was above 3, 4, 5, and 6 (less acidic)
over the 24 hour post-dose period when compared to baseline. In contradiction with the previous
studies, in a very large, well designed study, Orenstein, et al, detected no difference in efficacy
between lansoprazole and placebo for symptoms attributed to GERD in infants aged 1 to 12
months. It is difficult to rule out the use of lansoprazole because it appears to have very few side
effects. Further studies are recommended to determine its efficacy.
Esomeprazole has been recently studied in children. In a study by Croxtall, et al, GERD
symptoms improved significantly in children 1-11 years, but it was not studied in infants or
children less than 1 year old (Croxtall, et al, 2008). In another randomized trial, Gilger, et al,
showed that esomeprazole was well tolerated and symptoms of GERD were significantly
reduced during the active treatment (Gilger, et al, 2008). Omari, et al, studied the effects of
esomeprazole in infants 1 to 24 months old and found that it was well tolerated and showed acid
suppression but not a decrease in the actual symptoms of GERD (Omari, et al, 2007). In a study
focused on preterm and term neonates, Omari, et al, showed that esomeprazole caused significant
acid suppression but had no effect on the frequency, type, and extent of impedance-detected
bolus reflux. This study had no placebo control group so it is difficult to say that the
improvements were caused by the drug or that they would have simply occurred over time
(Omari, et al, 2009). Esomeprazole may be useful to treat GERD although there may not be
visible signs of improvement in terms of reflux episodes.

14

In one study by Canani, et al, long term use of gastric acid inhibitors including H2
receptor antagonists and proton pump inhibitors was related to community acquired pneumonia
and acute gastroenteritis. This is one reason that it is important to evaluate and re-evaluate the
need for medications (Canani, et al, 2006).
There are several treatments and medications that can be ruled out for use, or require
further study in order to be used, in the treatment of GERD in infants:


Cisapride cannot be recommended for use because of serious side effects. This product
has been removed from the market in the United States and is only available under
compassionate care (MacLennan, et al, 2009).



Domperidone cannot be recommended for use as its efficacy for the treatment of GERD
cannot be determined in the target population (Cresi, et al, 2008).



Metoclopramide has insufficient literature to support or oppose its use (Hibbs & Lorch,
2006).



Nizatidine may have limited use. Further studies should be done to determine the
efficacy of the drug (Orentstein, et al, 2005).



Erithromycin efficacy has not been determined in neonates and infants (Tighe, et al,
2010).



Baclofen has not been well studied in infants and needs further study (Omari, et al, 2006).



Bethanechol has insufficient evidence to recommend use (Tighe, et al, 2010).



Pantoprazole cannot be recommended as it is not studied in neonates and infants (Van
Wijk, et al, 2007).



Antacids and sucralfate, both aluminum containing, should not be used in infants
(Vandenplas, et al, 2005).
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The most difficult aspect of prescribing medications in neonates and infants is that with
very little data in this age group, it is difficult to decide which medication to use to treat GERD.
The medication chosen in the hospital setting appears to be driven more by physician preference
than anything else.
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Article
Title/Author
Pediatric Reflux: A
Burp Gone Bad
(2004, no author
listed)

…Maybe They
Can Be Avoided in
Some Kids With
Reflux (2008, no
author listed)

Managing gastro
oesophageal reflux
in infants (2009, no
author listed)

Type of
Article/
Study
Patient
handout; no
references
listed

Editorial
within
journal; short
synopsis of
study as a
child health
alert
Review
article

Participants

Theme/Treatment

Outcomes

Review article
focusing on
infants and
older children

Focuses on feeding and
formula types in
infants; Focus on
lifestyle changes,
medications in older
children

No outcomes listed

Infants with
suspected
GERD

Conservative therapy;
with no response, acid
suppression therapy

Infants

Treatment should be
initiated if growth is
affected.

Study strengths/
Weaknesses

Recommend
for use
in review
No

Level of
Research/
Grade
Level
VI/Grade
D

No
recommendation
for use

No outcomes listed

Level
VI/Grade
D

No
recommendation
for use

No

Dietary changes including
eliminating exposure to cow’s milk
even with breastfeeding if
symptoms severe; Short term
nasogastric feeding for infants with
poor weight gain; Thickening
agents may be used to decrease
incidents of regurgitation and
increased weight gain; Positioning
changes cannot be recommended;
Gaviscon can be recommended with
limitations; Cimetidine and
Famotidine can be recommended
limitedly for reduced regurgitation;
Omeprazole can be used to reduce
gastric acidity, acid exposure and
number and duration of gastro
oesophageal reflux episodes.

Level
I/Grade B

Review of
Randomized
Controlled
Trials for
Recommendatio
ns

Yes

17
Article
Title/Author

Type of
Article/Study

Participants

Theme/Treatment
Table I

Outcomes

Level of
Research
/Grade
Level
III/Grade
B

Developmental
Pharmacokinetics
and
Pharmacodynamics
of Nizatidine
(2004, AbdelRahman, et al)

Nonrandomized
trial; openlabel, single
dose or
multiple dose
trial

Children aged
5 days to 18
years and
adults aged 18
50 years

Nizatidine of various
dosages.

The biodisposition of Nizatidine in
children is similar to adults.
Response after a comparable
weight-based dose is equal and
potentially greater in children.

Infant Formulas
Thickened with
Carob Bean Gum
Causing FalsePositive
Galactomannan
Test Reactivity
(2008, Aceti, et al)
Protein Content
and Fortification of
Human Milk
Influence
Gastroesophageal
Reflux in Preterm
Infants (2009,
Aceti, et al)

Editorial
Comment

Hospitalized
children

Children on formulas
thickened with carob
bean gum can have
false-positive
Galactomannan test.

No outcomes listed

Level
VI/Grade
D

Case control
study

17 preterm
newborns fed
naïve and
fortified human
milk

Human Milk
fortification can
increase the protein
content in human milk
and influence
gastroesophageal reflux

An individualized fortification,
based on the analysis of the
composition of naïve human milk
could optimize both nutrient intake
and feeding intolerance

Level
III/Grade
B

Study strengths/
Weaknesses/
This study did
not test the
response but the
disposition of the
drug to determine
dosage. Limited
usage without
trials to discuss
efficacy.
No
recommendation
for use

Statistically
significant in
reflux episodes
with increased
protein content in
fortified human
milk (p<0.05)

Recommend
for use
in review
Not without
additional
trials to
discuss
efficacy of
Nizatidine
for
treatment of
GERD
No

Yes
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Article
Title/Author

Type of
Article/Study

Participants

Theme/Treatment
Table I

Outcomes

Level of
Research
/Grade
Level
VI/Grade
D

Study strengths/
Weaknesses/

Anti-reflux or
Anti-regurgitation
Milk Products for
Infants and Young
Children: a
Commentary by
the ESPGHAN
Committee on
Nutrition (2004,
Agostini, C. on
behalf of
ESPGHAN
Committee of
Nutrition)
The Reflex to Treat
Reflux – Let’s be
Conservative
Regarding
Gastroesophageal
Reflux (GER)!
(2008, Balistreri,
W.F.)
Lack of AgeAppropriate RCTs
Make EvidenceBased Treatment
Difficult (2005,
Bell, A. L.)

Editorial
comment

Infants and
young children

Formula with
thickening agents to
decrease regurgitation
and reflux

No outcomes noted

Editorial
comment

Infants and
Children

Conservative therapy
for GERD should be
used in infants.
Medications may be
overprescribed in this
population

No outcomes noted

Level
VI/Grade
D

No
recommendation
for use

No

Editorial
comment

Infants

Treatment with
medications if
conservative therapy
fails is not well
supported with clinical
trials

No outcomes noted

Level
VI/Grade
D

No
recommendation
for use

No

Formulas with
thickening agents
should not be
used
indiscriminately.

Recommend
for use
in review
No
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Article
Title/Author

Type of
Article/Study

Participants

Theme/Treatment
Table I

Gastro
oesophageal Reflux
Disease in Preterm
Infants: Current
Management and
Diagnostic
Dilemmas (2009,
Birch & Newell)

Review
Article

Preterm Infants

Conservative therapy
for treatment should be
utilized before moving
to more advanced
treatments

Omeprazole for
Gastroesophageal
Reflux Disease in
the First 2 Years of
Life: A Dose
Finding Study with
Dual Channel pH
Monitoring (2007,
Bishop, et al)

Prospective
Dose-finding
study

Children under
2 years of age

Treatment with
Omeprazole

Outcomes

Prone or left-lateral positioning
reduces GORD in preterm infants,
should only be used in hospitalized
infants with cardio respiratory
monitoring. Evidence is limited for
the beneficial effects of thickeners.
Carob-based thickeners reduce non
acid reflux in older infants. No
good evidence for the use of
Erithromycin. Ranitidine is
successful in reducing gastric
acidity. Cimetidine not
recommended in preterm infants.
There is no evidence that Proton
pump inhibitors are more effective
than ranitidine in treating GORD
and their safety is not well studied.
Domperidone not recommended in
preterm infants.
Omeprazole is an effective
treatment for gastroesophageal
reflux disease in children younger
than 2 (p<0.05) although sample
size was small (10 children).

Level of
Research
/Grade
Level
I/Grade
B

Study strengths/
Weaknesses

Level
III/Grade
B

Used pH studies
to determine
effectiveness, no
serious
complications or
side effects.

Review of trials
for preterm
infants;
Suggested
management
strategy from
conservative
therapy to more
advanced
treatments.

Recommend
for use
in review
Yes

Yes
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Article
Title/Author

Type of
Article/Study

Participants

Theme/Treatment
Table I

Extraesophageal
Reflux in Children
(2006, Brodsky and
Carr)

Review
article

Children
(infants to
adolescents)

Conservative
treatments including
environmental
exposures and feeding
alterations should be
considered before
medications

Therapy with
Gastric Acidity
Inhibitors Increases
the Risk of Acute
Gastroenteritis and
CommunityAcquired
Pneumonia in
Children (2006,
Canani, et al)

Nonrandomized
control trial

Children aged
4-36 months

Treatment of
gastroesophageal reflux
with gastric acid
inhibitors.

Outcomes

Infants: Soy, partially hydrolyzed,
and elemental formulas can be
helpful. Small, slow, and frequent
feedings in a relaxed environment
are helpful to infants with delayed
gastric emptying. Thickening of
formula should be avoided.
Children aged 2-11 years: Spicy,
acidic, caffeinated and fatty foods
should be avoided. Carbonated
beverages should be avoided.
Little support for medications in
children noted.
The use of gastric acid inhibitors is
associated with an increased risk of
acute gastroenteritis and
community-acquired pneumonia in
children with GERD.

Level of
Research
/Grade
Level
I/Grade
B

Level
III/Grade
B

Study strengths/
Weaknesses
Review article.
Studies not cited
within article.

Large sample
size. Low pvalues for
statistical
significance. Use
caution when
prescribing
gastric acid
inhibitors.

Recommend
for use
in review
Yes/Limited

Yes
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Article
Title/Author

Type of
Article/Study

Participants

Theme/Treatment
Table I

Outcomes

Level of
Research
/Grade
Level
II/Grade
B

Study strengths/
Weaknesses

Comparison of the
Effect of a
Cornstarch
thickened Formula
and Strengthened
Regular Formula
on Regurgitation,
Gastric Emptying
and Weight Gain in
Infantile
Regurgitation
(2007, Chao &
Vandenplas)
Effect of CerealThickened Formula
and Upright
Positioning on
Regurgitation,
Gastric Emptying,
and Weight Gain in
Infants with
Regurgitation
(2007, Chao &
Vandenplas)
Patience is a Virtue
in the Management
of
Gastroesophageal
Reflux (2009,
Clark & Spitzer)

Prospective
Randomized
Trial – infant
used as own
control – for
two different
interventions

Infants with
regurgitation/
vomiting > 3
times per day

Cornstarch thickened
formula vs. 25%
strengthened regular
infant formula (five
scoops instead of 4
scoops to 120mL of
water).

Cornstarch-thickened formula
feeding decreases the frequency of
regurgitation/vomiting, provides
better body weight gain and has an
accelerated gastric emptying in
comparison to a 25% strengthened
regular formula in infants with
regurgitation.

Prospective
randomized
trial

Infants 2 to 6
months of age
with
regurgitation or
vomiting at
least 3 times
per day

Cereal-thickened
formula versus
postprandial upright
position for 90 minutes.

Cereal-thickened formula is
significantly more efficacious than
postural therapy in decreasing the
frequency of regurgitation. Cereal
thickened formula also results in an
increased caloric intake
(approximately 25%) related to
increased gain in weight and length
in comparison with regular formula
and positioning therapy.

Level
II/Grade
B

Fairly large
sample size.
Focused on
infants.
Statistically
significant
results.

Yes

Editorial
comment

Children

Conservative therapies
often decrease
symptoms of reflux –
more advanced
therapies may not be
necessary.

No outcomes noted

Level
VI/Grade
D

No
recommendation
for use

No

Fairly large
sample size,
focused on
infants, with low
p values for
statistical
significance.
Randomized trial
using infant as
own control.

Recommend
for use
in review
Yes
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Table I
Theme/Treatment

Article
Title/Author

Type of
Article/Study

Participants

Outcomes

Level of
Research
/Grade
Level
III/Grade
B

Study strengths/
Weaknesses

Starch Thickening
of Human Milk is
Ineffective in
Reducing the
Gastroesophageal
Reflux in Preterm
Infants: A
crossover Study
Using Intraluminal
Impedance (2006,
Corvaglia, et al)
The Effect of Body
Positioning on
Gastroesophageal
Reflux in
Premature Infants:
Evaluation by
Combined
Impedance and pH
Monitoring (2007,
Corvaglia, et al)
Short-term Effect
of Domperidone on
Gastroesophageal
Reflux in
Newborns
Assessed by
Combined
Intraluminal
Impedance and pH
Monitoring (2008,
Cresi, et al)

Crossover
Trial

Preterm infants

Thickening of fortified
human milk by
precooked starch.

Thickening human milk by
precooked starch is ineffective in
reducing gastroesophageal reflux in
premature infants

Nonrandomized,
using subject
as their own
control

Preterm infants

Positioning in the prone
or left lateral position
and its effect on
gastroesophageal reflux

Placing premature infants in the
prone or left lateral position in the
postprandial period is a simple
intervention to limit GER.

Level
III/Grade
B

Small sample
size but
statistically
significant
results. Non
invasive
intervention.

Yes

Randomized
controlled
trial

Term and
Preterm
neonates

Use of Domperidone to
decrease the number of
reflux episodes

There was a paradoxical increase in
the number of GER episodes in the
treatment group. This treatment
may not be efficacious in this age
bracket.

Level
II/Grade
B

Small sample
size with
statistically
significant
results. Would
not use this
treatment in this
age group as
more studies are
needed.

Yes

Small sample
size. Because of
risk of
necrotizing
enterocolitis with
thickened milk in
pre-term infants,
would not
recommend
starch thickening

Recommend
for use
in review
Yes
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Article
Title/Author

Type of
Article/Study

Participants

Gaviscon for
Gastro
oesophageal Reflux
in Infants: a Poorly
Effective
Treatment? (2006,
Cresi, et al)
Lansoprazole In
the Treatment of
Gastro
0oesophageal
Reflux Disease in
Children and
Adolescents (2005,
Croom & Scott)
Esomeprazole in
Gastroesophageal
Reflux Disease in
Children and
Adolescents (2008,
Croxtall, et al)

Editorial
comment

Infants

Gaviscon for reflux
treatment

No outcomes noted

Open-label,
uncontrolled
trial

Children aged
1-11 years.
Adolescents
aged 12-17
years.

Drug treatment (proton
pump inhibitor) that
inhibits gastric acid
secretion

The effectiveness and tolerability of
Lansoprazole has been established
in pediatric patients aged 1-17 years
for short-term treatment of
symptomatic GORD and erosive
oesophagitis.

Level
III/Grade
B

Does not look at
infants and
children less than
1 year of age.
Not a
randomizedcontrolled trial.

Yes/Limited
to children 1
year old or
older

Randomized,
double-blind,
multicenter
trial

Children aged
1-11 years.
Adolescents
aged 12-17
years.

Drug treatment (proton
pump inhibitor) that
inhibits gastric acid
secretion

Level
II/Grade
B

Does not look at
infants and
children less than
1 year of age.

Yes/Limited
to children 1
year old or
greater.

Randomized,
placebo
controlled,
double blind
study

Children under
12 months of
age.

The influence of
Gaviscon Infant on
Gastro-oesophageal
Reflux in infants

GERD symptoms significantly
improved with Esomeprazole in
children aged 1-11 years and
adolescents aged 12-17 years in.
Esomeprazole was generally well
tolerated in both children and
adolescents.
Results showed a marginal but
significant difference between
Gaviscon Infant and placebo in
average reflux height. The
treatment did not show a significant
difference in median number of
reflux events per hour, acid reflux
events per hour, minimum distal or
proximal pH, total acid clearance
time per hour and total reflux
duration per hour between treatment
and placebo.

Level
II/Grade
B

Good study
design, small
number of
subjects. Does
not appear to be a
perceived clinical
benefit to the
treatment’s use.

Yes

Effect of Gaviscon
Infant on Gastro
oesophageal Reflux
in Infants Assessed
by Combined
Intraluminal
Impedance/pH
(2005, Del Buono,
et al)

Theme/Treatment

Outcomes

Table I

Level of
Research
/Grade
Level
VI/Grade
D

Study strengths/
Weaknesses
No
recommendation
for use

Recommend
for use
in review
No
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Table I
Theme/Treatment

Article
Title/Author

Type of
Article/Study

Participants

Outcomes

Level of
Research
/Grade
Level
VI/Grade
D

Does Treating
Gastroesophageal
Reflux Cause
Pneumonia? (2005,
Federico, M)

Editorial
Comment

Infants and
children

Relationship between
proton pump inhibitor
or H2 blocker use for
the treatment of GER
and communityacquired pneumonia

No outcomes noted

Systematic
Review: Proton
Pump Inhibitors for
the Treatment of
Gastroesophageal
Reflux in Infants
(2008,
GieruszczakBialek, et al)
Safety and
Tolerability of
Esomeprazole in
Children with
Gastroesophageal
Reflux Disease
(2008, Gilger, et al)
Gastroesophageal
Reflux Disease:
Could Intervention
in Childhood
Reduce the Risk of
Later
Complications?
(2004, Gold, B. D.)

Systematic
Review

Infants

Review to evaluate the
efficacy and safety of
proton pump inhibitors
for the treatment of
GERD in infants.

Multicenter,
randomized,
uncontrolled,
double-blind
study.

Children aged
1 to 11 years.

Review
article

Children

Study strengths/
Weaknesses

Recommend
for use
in review
No

No
recommendation
for use

There is insufficient evidence to
determine the role of proton pump
inhibitor therapy for treatment of
GERD in infants. Further trials are
needed addressing both safety and
efficacy of proton pump inhibitors
in infants.

Level
I/Grade
A

Review of
randomized
controlled trials.

Yes

Treatment with
Esomeprazole for
gastroesophageal reflux
disease

In children with endoscopically
proved GERD, Esomeprazole was
generally well tolerated. Frequency
and severity of GERD-related
symptoms significantly reduced
during active treatment period.

Level
II/Grade
B

Well designed
study. Large
sample size.
Low P values for
statistical
significance.

Yes/Limited

Do treatments for
gastroesophageal reflux
disease in children
reduce the risk of later
complications in
adulthood?

Treatments for pediatric GERD are
based on the clinical indications of the
specific child with GERD and range
from conservative measures
(positioning, formula changes) to
pharmacotherapy to surgery. Proton
pump inhibitors are safe, effective, and
due to their superiority in resolving acid
related disease, could be appropriate
interventions in GERD occurring in
childhood to successfully prevent long
term sequelae.

Level
I/Grade
B

Review article
with current data.
No specific
reference to
infants.

Yes/Limited
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Article
Title/Author

Type of
Article/Study

Participants

Theme/Treatment

Treatment of
Gastroesophageal
Reflux Disease
(2006, Guimaraes,
et al)

Review
article

Infants and
Children

Treatment of
gastroesophageal reflux
disease with emphasis
on pharmacological
aspects.

Gastroesophageal
Reflux and
Prokinetic Agents
(2005, Hammer,
D.)

Review
article

Preterm and
term infants

Treatment of GER with
prokinetic agents.

Talk is Cheap,
Often Effective:
Symptoms in
Infants Often
Respond to Non
pharmacologic
Measures (2008,
Hassall, E.)

Editorial
comment

Infants

Non-pharmacologic
treatment of
gastroesophageal reflux

Outcomes

Table I
Left lateral and prone positioning
should only be considered in infants
if the risks related to GERD
outweigh the risk of sudden infant
death syndrome. There is no
benefit to inclined positions.
Thickened formulas may reduce
clinical symptoms but not actual
reflux in the esophagus. Avoiding
spicy, caffeinated foods and
chocolate is recommended in older
children. H2 receptor antagonists
and proton pump inhibitors have
some support for use.
Non-pharmacologic agents are the
first step in treating GER including
positioning and feeding
interventions. Bethanechol is not
recommended for treatment.
Erythromycin is not recommended
for treatment. Metoclopromide can
be recommended for use.
No outcomes noted

Level of
Research
/Grade
Level
I/Grade
A

Study strengths/
Weaknesses
Review article of
controlled and
randomized trials
and review
articles.

Recommend
for use
in review
Yes

Level
I/Grade
B

Review article
looking at
preterm and term
infants.

Yes

Level
VI/Grade
D

No
recommendation
for use

No
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Article
Title/Author

Type of
Article/Study

Participants

Theme/Treatment
Table I

Characteristics of
Children Receiving
Proton Pump
Inhibitors
Continuously for
Up to 11 Years
Duration (2007,
Hassall, et al)

Retrospective
cohort study

Children aged
less than 1 year
to 17 years old.

Long-term treatment
with proton pump
inhibitors for
gastroesophageal reflux
disease.

Domperidone
Versus Cisapride in
the Treatment of
Infant
Regurgitation and
Increased Acid
Gastro
oesophageal
Reflux: A Pilot
Study (2009,
Hegar, et al)
Natural Evolution
of Infantile
Regurgitation
Versus the Efficacy
of Thickened
Formula (2008,
Hegar, et al)

Investigatorblinded,
prospective
comparative
trial.

Infants
regurgitating
more than 4
times per day
for more than 2
weeks after
conservative
treatment
failure.

Prokinetic therapy for
the treatment of
gastroesophageal reflux
symptoms.

Prospective,
blinded,
randomized
1-month
intervention
trial

Healthy, termborn, formulafed infants
aged 1 to 3
months.

Therapy of parental
reassurance in
combination with
standard infant
formula, 5 grams of
rice cereal added to
100mL standard
formula, or formula
manufactured with
bean gum as a
thickening agent.

Outcomes

Children with long term proton
pump inhibitor use have few
adverse reactions and
discontinuation of the drug is
seldom indicated. Preliminary data
suggest that proton pump inhibitors
may be efficacious and safe for
continuous use for up to 11 years
duration in children.
The frequency of regurgitation
decreased in both groups although
more rapidly in the Cisapride group.
The decrease in regurgitation was
still significant after 1 month. The
natural decrease in the incidence of
regurgitation induced by age should
also be considered.

Thickening of formula decreases
regurgitation, but not significantly.
Parental reassurance remains the
cornerstone of the treatment of
infant regurgitation.

Level of
Research
/Grade
Level
III/Grade
B

Study strengths/
Weaknesses

Recommend
for use
in review

Cohort study
with large sample
size.

Level
II/Grade
B

Pilot study with
small sample
size. Blinded,
prospective,
comparative trial
with no controls.

Yes/Limited

Level
II/Grade
B

Sample size of 60
infants.
Randomized trial
with statistically
significant
results.

Yes
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Article
Title/Author

Type of
Article/Study

Participants

Theme/Treatment
Table I

Outcomes

Level of
Research
/Grade
Level
III/Grade
B

Study strengths/
Weaknesses

Pharmacokinetics
and
Pharmacodynamics
of Lansoprazole in
Children 13 to 24
Months Old With
Gastroesophageal
Reflux Disease
(2007, Heyman, et
al)
Metoclopramide
for the Treatment
of
Gastroesophageal
Reflux Disease in
Infants: A
Systematic Review
(2006, Hibbs &
Lorch)
The Effect of
Thickened-Feed
Interventions on
Gastroesophageal
Reflux in Infants:
Systematic Review
and Meta-analysis
of Randomized,
Controlled Trials
(2008, Horvath, et
al)

Subanalysis
of 8 toddlers
who
participated
in a phase I/II
open-label,
multicenter
US study

8 toddlers
between 13 and
24 months.

Treatment with
Lansoprazole increased
if symptomatic after 2
weeks of treatment

Lansoprazole displays
pharmacokinetic and
pharmacodynamic parameters in
children between 13 and 24 months
of age that are similar to those
results observed in older children as
well as adults. Further studies are
needed to confirm results.

Systematic
Review

Infants

Treatment with
Metoclopramide for
gastroesophageal reflux
disease.

11 prospective trials, 5 were
randomized, blinded clinical trials.
The current literature is insufficient
to either support or oppose the use
of Metoclopramide for
gastroesophageal reflux disease in
infants.

Level
I/Grade
A

Inconclusive
recommendation
for usage.
Further trials
needed.

Yes

Systematic
Review with
meta-analysis

Infants

Effect of feed
thickeners on
gastroesophageal reflux
disease.

Thickened food is only moderately
effective in treating
gastroesophageal reflux in term
infants. The data did not allow the
authors to conclude whether any
particular thickening agent is
definitely more effective than
another.

Level
I/Grade
A

Used
Randomized
Controlled Trials.

Yes/Limited

Very small
sample size.
Non-randomized
trial.

Recommend
for use
in review
Yes/Limited
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Article
Title/Author

Type of
Article/Study

Participants

Feed Thickener for
Newborn Infants
With Gastro
oesophageal Reflux
(2009, Huang, et
al)

Systematic
Review

Newborn
Infants

Gastroesophageal
Reflux in Preterm
Infants: How Acid
Should It Be?
(2008, Indrio, et al)

Editorial
comment

Preterm Infants

Update on Drugs
for Gastro
oesophageal Reflux
Disease (2007,
Keady, S.)

Review
article

Infants,
children and
adolescents

Theme/Treatment
Table I

Outcomes

Level of
Research
/Grade
Level
I/Grade
A

Study strengths/
Weaknesses
Reviewed
randomized,
controlled trials.

Recommend
for use
in review
Yes/Limited

The use of feed
thickeners in reducing
signs and symptoms of
GOR, acid episodes on
pH monitoring and
histological evidence of
oesophagitis.
Effect of proton pump
inhibitors on
gastroesophageal
reflux.

No suitable studies were found for
inclusion in the review.

No outcomes noted.

Level
VI/Grade
D

No
recommendation
for use.

No

Review of management
techniques to treat
gastro-oesophageal
reflux disease.

Antacids can be used as first line
medication although there are not
long-term effects. Gaviscon Infant
can be used. Domperidone shows
very little efficacy. Erithromycin
efficacy in neonates and infants has
not been supported by clinical trials.
Metoclopromide has limited use as
adverse effects are severe. The
product license for Cisapride has
been withdrawn. Ranitidine has
efficacy in mild oesophagitis.
Proton pump inhibitors such as
Lansoprazole and Omeprazole show
benefit but children seem to
metabolize them quicker so a daily
dose regimen may be necessary.
Lack of child suitable formulations
can limit their use.

Level
I/Grade
B

Review did not
include only
randomized
controlled trials.

Yes
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Article
Title/Author

Type of
Article/Study

Participants

Theme/Treatment

Clinical Response
to 2 Dosing
Regimens of
Lansoprazole in
Infants With
Gastroesophageal
Reflux (2008,
Khoshoo and
Dhume)

Randomized
Controlled
Trial

Infants older
than 3 months
born at term.

To determine the
clinical efficacy of 2
dosing regimens of
Lansoprazole in infants
with GERD.

Soothing Your
Breastfed Baby
With Reflux (2009,
Kombol, P.)

Parent
Handout

Breastfed
infants up to 1
year of age

Feeding interventions
to deal with
gastroesophageal
reflux.

Treating GER in
Children Younger
Than Two Years
(2005, Kripke, C.)

Editorial
comment

Children
younger than 2
years.

Conservative therapy
for the treatment of
GER.

FDA Approves
Nexium for Use in
Children Ages 1-11
Years (2008, Lang,
L.)

Bulletin

Children aged
1-11 years.

Treatment approved for
use in gastroesophageal
reflux disease.

Outcomes

Table I
The two different doses had better
results for infants than those in the
control group. The group with the
twice daily doses showed
significant improvement in a shorter
period of time. There may be a
faster onset of symptom
improvement but eventually there
was no difference between the two
doses overall.
No outcomes noted

Level of
Research
/Grade
Level
II/Grade
B

Study strengths/
Weaknesses
Randomized
controlled trial.
66 participants in
the study,
reasonable
sample size.

Recommend
for use
in review
Yes

Level
VI/Grade
D

No
recommendation
for use.

No

No outcomes noted.

Level
VI/Grade
D

No
recommendation
for use.

No

No outcome noted.

Level
VI/Grade
D

No
recommendation
for use.

No
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Article
Title/Author

Type of
Article/Study

Participants

Theme/Treatment
Table I

Outcomes

Level of
Research
/Grade
Level
III/Grade
B

Study strengths/
Weaknesses

Use of Medications
for
Gastroesophageal
Reflux at
Discharge Among
Extremely Low
Birth Weight
Infants (2008,
Malcolm, et al)
Drugs for the
Treatment of
Gastro
oesophageal
Reflux: In Search
of Clear Evidencebased Indications
(2007, Marchetti,
et al)
Gastroesophageal
Reflux in Preterm
Infants: Is
Positioning the
Answer? (2007,
Martin, et al)

Retrospective
cohort
analysis

Extremely low
birth weight
infants at
corrected ages
of 18 to 22
months.

Medication usage in the
treatment of
gastroesophageal reflux
disease and the effect
on growth or
development at the
time of follow-up
evaluations.

Use of antireflux medications at the
time of discharge for extremely low
birth weight infants does not seem
to have effects on growth or
development. Medications included
were antacids and H2 receptor
antagonists.

Editorial
comment

Infants

Drugs for the treatment
of gastroesophageal
reflux disease.

No outcomes noted.

Level
VI/Grade
D

No
recommendation
for use.

No

Editorial
comment

Preterm Infants

Positioning as the
treatment for
gastroesophageal
reflux.

No outcomes noted.

Level
VI/Grade
D

No
recommendation
for use.

No

Difficulty in
Defecation in
Infants with
Gastroesophageal
Reflux Treated
with Smaller
Volume Feeds
Thickened with
Rice Cereal (2005,
Mascarenhas, et al)

Nonrandomized,
case control
study.

Full-term,
neurologically
intact infants
less than 5
months of age.

Treatment of rice cereal
thickened, small
volume feeds for
gastroesophageal reflux
and its relation to
difficulty with
defecation.

Smaller volume feeds thickened
with rice cereal was effective in
alleviating symptoms of GER but
about one third of the infants had
difficulty with defecation.
Changing rice to oatmeal resulted in
partial or complete improvement in
defecation difficulty in about 70%
of these infants without causing a
change in symptoms of
gastroesophageal reflux.

Level
I/Grade
B

Study design
limited. The
measurement of
symptoms of
gastroesophageal
reflux was likely
inadequate.

Yes/Limited

Large sample
size. Medication
types not broken
down into
groups.

Recommend
for use
in review
Yes
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Article
Title/Author

Type of
Article/Study

Participants

Theme/Treatment

Outcomes

Cisapride
Treatment for
GastroOesophageal
Reflux in Children
(2009, MacLennan,
et al)

Systematic
Review

Children
diagnosed with
gastro
oesophageal
reflux

Does Cisapride reduce
symptoms of gastro
oesophageal reflux?

Ten trials in total met the inclusion
criteria for this systematic review.
There was no clear evidence that
Cisapride reduces symptoms of
gastro-oesophageal reflux.

Gastroesophageal
Reflux (2007,
Michail, S.)

Review
article

Pediatric
population

Appropriate therapies
for gastroesophageal
reflux disease.

Reassurance and educating the
family in an otherwise healthy
infant can be the only intervention
in some. Lifestyle changes can be
helpful for children with mild
disease. Feeding interventions
would be the next intervention for
moderate disease. Prone
positioning can be used only when
there is no risk of death from SIDS.
Antacids can be used for short-term
therapy and relieve of symptoms.
H2 receptor antagonists have
demonstrated efficacy esophagitis
but not as well as proton pump
inhibitors. Surface agents should be
used with caution.

Table I

Level of
Research
/Grade
Level
I/Grade
A

Level
I/Grade
B

Study strengths/
Weaknesses
Review used
randomized
controlled trials
for review.
Cisapride not
recommended for
use and treatment
is limited to
patients treated
within a clinical
trial program.
Review article.
Not limited to
randomized
controlled trial
review.

Recommend
for use
in review
Yes

Yes
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Article
Title/Author

Type of
Article/Study

Participants

Theme/Treatment
Table I

Outcomes

Level of
Research
/Grade
Level
III/Grade
B

Study strengths/
Weaknesses

Effect of Formula
Thickened with
Reduced
Concentration of
Locust Bean Gum
on
Gastroesophageal
Reflux (2007,
Miyazawa, et al)
Effect of Locust
Bean Gum in Anti
regurgitant Milk on
the Regurgitation
in uncomplicated
Gastroesophageal
Reflux (2004,
Miyazawa, et al)
Effect of Formula
Thickened with
Locust Bean Gum
on Gastric
Emptying in
Infants (2006,
Miyazawa, et al)

Non
randomized
case-control
study.

Infants less
than 2 months
old who had
three or more
episodes of
regurgitation or
vomiting per
day.

Treatment with locust
bean gum thickened
formula for
gastroesophageal reflux
disease.

The median number of regurgitation
episodes decreased significantly
(p=o.ooo48) with the thickened
formula. No significant difference
was evident in feeding volume and
time, body weight gain, or gastric
emptying rate between thickened
and non-thickened formula.

Randomized,
controlled
crossover
trial

Infants with
daily
regurgitation
but no other
medical
problems

Effect of different
concentrations of locust
bean gum in anti
regurgitant milk on
gastroesophageal
reflux.

Both concentrations of AR formulas
decreased the number of
regurgitation episodes by about
50%. The decreased concentration
of locust bean gum may be easier
for the infant to suck through the
nipple.

Level
II/Grade
B

Small sample
size (30) but a
randomized
controlled
crossover trial.

Yes

Randomized
controlled
trial

Infants with
three or more
episodes of
regurgitation
per day without
other major
medical
problems.

Two different formulas
with two different
concentrations of locust
bean gum compared to
a control formula
without locust bean
gum and their effect on
gastric emptying.

Thickened formula with locust bean
gum slowed gastric emptying more
than one with a reduced
concentration of this thickening
agent and more than a formula
without a thickening agent.
However, thickened formulas
reduced the number of regurgitation
episodes after feeding, without
causing any complications.

Level
II/Grade
B

Randomized,
controlled trial
with fair sample
size. Formulas
thickened with
locust bean gum
are not readily
available in the
United States.

Yes/Limited

Small study
number (20), but
used infants as
their own control.

Recommend
for use
in review
Yes
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Article
Title/Author

Type of
Article/Study

Participants

Theme/Treatment
Table I

Effects of a
Prethickened
Formula on
Esophageal pH and
Gastric Emptying
of Infants with
GER (2007,
Moukarzel, et al)

Randomized
controlled
trial

74 healthy
infants less
than 6 months
old with GER.

Prethickened formula
used for infants with
GER and their effect on
gastric pH and gastric
emptying. A reflux
index score was used to
measure severity of
reflux disease.

Gastroesophageal
Reflux in Infants:
Can a Simple Left
Side Positioning
Strategy Help This
Diagnostic and
Therapeutic
Conundrum?
(2008, Omari, T.)

Review
Article

Preterm and
term infants
from 0-6
months of age.

Left-sided positioning
as a nonpharmacological
approach to the
treatment of GER
related symptoms.

Outcomes

This studies was able to show a
significant (p<0.01) improvement in
the reflux index of infants who
received the AR (anti-regurgitation,
pre-thickened) formula. There was
also significantly faster clearance
from the esophagus of AR than
regular formula which was a
difference of almost one minute.
The longest reflux episode of the
AR fed group was significantly
shorter than the longest reflux
episode of the regular formula fed
group. The study suggests that AR
formula is more effective in
reducing the reflux index when
GER is more severe.
Left side positioning will reduce the
number of reflux events in infants
and is likely to complement
standard proton pump inhibitor
therapy. It has not been proven that
left side positioning will reduce
symptoms due to gastroesophageal
reflux in infants. Left side
positioning can increase the risk of
SIDS and should only be used for
short periods of time (2 hours post
prandial) and not overnight when an
infant is unobserved.

Level of
Research
/Grade
Level
II/Grade
B

Study strengths/
Weaknesses

Level
I/Grade
B

Review article
focusing on
position in the
treatment. Not a
systematic
review.

Randomized
controlled trial
with moderate
sample size.
Excellent P
values for
statistical
significance.

Recommend
for use
in review
Yes

Yes
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Article
Title/Author

Type of
Article/Study

Participants

Pharmacokinetics
and Acidsuppressive Effects
of Esomeprazole in
Infants 1-24
Months Old with
Symptoms of
Gastroesophageal
Reflux Disease
(2007, Omari, et
al).

Single-blind,
randomized,
parallelgroup study

50 infants 1 to
24 months old
with symptoms
of GERD

Theme/Treatment
Table I
Treatment with
esomeprazole and its
effect on GERD

Outcomes

Oral treatment with esomeprazole
0.25 mg/kg and 1 mg/kg was well
tolerated and provided dose-related
acid suppression, dose-related
exposure to esomeprazole and
decreased esophageal acid exposure
in infants. The dosage of 1 mg/kg
provided the most effective acid
suppression, normalizing
esophageal acid exposure in this
group of patients. The effect of
esomeprazole on symptoms of
GERD in the infants participating in
the trial were inconclusive because
there were no obvious changes in
vomiting, choking/gagging and
irritability/crying symptom scores
during 1 week of treatment.

Level of
Research
/Grade
Level
II/Grade
B

Study strengths/
Weaknesses
Randomized
study with good
sample size. No
placebo control
within study.

Recommend
for use
in review
Yes
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Article
Title/Author

Type of
Article/Study

Participants

Theme/Treatment
Table I

Pharmacodynamics
and Systemic
Exposure of
Esomeprazole in
Preterm Infants and
Term Neonates
with
Gastroesophageal
Reflux Disease
(2009, Omari, et
al).

Open-label
trial

Preterm infants
and term
neonates aged
< 1 month term
age.

Treatment with
esomeprazole for
GERD

Effect of Baclofen
on Esophagogastric
Motility and
Gastroesophageal
Reflux in Children
with
Gastroesophageal
Reflux Disease: A
Randomized
Controlled Trial
(2006, Omari, et
al).

Randomized
Controlled
Trial

Children aged
2.6 years to
17.4 years.

Trial to look at the
effects of Baclofen on
motility and
gastroesophageal
reflux.

Outcomes

Esomeprazole 0.5 mg/kg given once
daily showed significant acid
suppression but had no effect on the
frequency, type, and extent of
impedance-detected bolus reflux.
Despite increased systemic
exposure, treatment with
esomeprazole was well tolerated,
and significant acid suppression was
apparent, indicating that the chosen
dosage of 0.5 mg/kg once daily is
appropriate in the preterm infant
and term neonate population. The
number of symptoms overall, as
well as individual symptoms of
gagging and irritability/crying, were
significantly reduced on therapy.
Baclofen significantly reduced the
rate of triggering of transient lower
esophageal sphincter relaxation
(TLESR) and GER but did not
reduce the rate of swallowing, the
pattern of peristalsis or the
magnitude of lower esophageal
sphincter pressure compared with
placebo. Baclofen reduced the
triggering of TLESRs in children
and this was associated with a
reduced number of GER episodes.
Baclofen also increases gastric
emptying.

Level of
Research
/Grade
Level
III/Grade
B

Level
II/Grade
B

Study strengths/
Weaknesses
No placebo
control group.
Difficult to say
that treatment
caused
improvements
versus
improvement that
might have
occurred over
time. Good
sample size.

Randomized
controlled trial.
30 children
enrolled. Does
not specifically
study the effects
on infants. This
study did not
address how well
long term therapy
with Baclofen
would be
tolerated in
children.

Recommend
for use
in review
Yes

Yes/Limited
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Article
Title/Author

Type of
Article/Study

Participants

Theme/Treatment
Table I

Outcomes

Level of
Research
/Grade
Level
II/Grade
B

Study strengths/
Weaknesses

Nizatidine for the
Treatment of
Pediatric
Gastroesophageal
Reflux Symptoms:
An Open-Label,
Multiple-Dose,
Randomized,
Multicenter
Clinical Trial in
210 Children
(2005, Orenstein,
et al).
Infants and Proton
Pump Inhibitors:
Tribulations, No
Trials (2007,
Orenstein &
Hassall).

Randomized,
parallel
group, openlabel,
multipledose,
multicenter
study.

Children aged
5 days through
12 years and 13
years through
18 years.

Treatment with
Nizatidine in various
doses and formulations
for gastroesophageal
reflux disease.

Tolerability of nizatidine is
supported in the current study. 8
weeks of treatment with nizatidine
were accompanied by complete
resolution of all reflux symptoms in
nearly one third of the children in
the treatment groups. There was an
overall improvement in symptoms
and a decrease in antacid use in the
pediatric study population.
Formulation did not appear to alter
tolerability or effectiveness.

Editorial
Comment/
Expert
opinion

Infants

Treatment with proton
pump inhibitors for the
treatment of
gastroesophageal
reflux.

No outcome noted.

Level
VI/Grade
D

No
recommendation
for use.

No

Multicenter,
Double-Blind,
Randomized,
Placebo-Controlled
Trial Assessing the
Efficacy and Safety
of Proton Pump
Inhibitor
Lansoprazole in
Infants with
Symptoms of
Gastroesophageal
Reflux Disease
(2009, Orenstein,
et al).

Doubleblind,
randomized,
placebocontrolled
trial

Infants aged 28
days to < 12
months and
preterm infants
with corrected
age of 44
weeks PCA but
< 12 months.

Treatment with
lansoprazole for
gastroesophageal reflux
disease.

This study detected no difference in
efficacy between lansoprazole and
placebo for symptoms attributed to
GERD in infants aged 1 to 12
months. Significant adverse events,
particularly lower respiratory tract
infections occurred more frequently
with lansoprazole than with
placebo.

Level
II/Grade
B

Good study
design. Power
was suggested at
160 subjects, 162
enrolled. Crying
was a part of the
inclusion criteria
and is
nonspecific for
GERD.

Yes

Open label
design. Large
sample size.
Multiple dosing
and formulation
groups modulate
the power of the
study.

Recommend
for use
in review
Yes/Limited
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Article
Title/Author

Type of
Article/Study

Participants

Efficacy of
Conservative
Therapy as Taught
in the Primary Care
Setting for
Symptoms
Suggesting Infant
Gastroesophageal
Reflux (2008,
Orenstein &
McGowan).

40 of the 50
infants
enrolled in
the
Prospective,
double-blind,
placebocontrolled
randomized
clinical trial
of an oral
solution of an
H2RA.
Systematic
review of
randomized
controlled
trials.

Infants

Conservative therapy
taught in the primary
care setting and its
impact on symptoms of
gastroesophageal reflux
disease.

Two weeks of conservative therapy
measures can improve symptoms in
78% of infants with GERD who are
seen and treated in the primary care
setting, normalizing symptoms in
24%.

Children aged
1 month to 11
years old.

Domperidone for the
treatment of
gastroesophageal reflux
disease

There was limited evidence
available. There was no robust
evidence of efficacy for the
treatment of GOR with
domperidone in young children.

Level
I/Grade
A

Review of
randomized
controlled trials.

Yes

Babies

The use of carob bean
gum thickeners for
treatment of
gastroesophageal
reflux.

No outcomes noted.

Level
VI/Grade
D

No
recommendation
for use.

No

Should
Domperidone Be
Used For the
Treatment of
Gastro
oesophageal Reflux
in Children?
Systematic Review
of Randomized
Controlled Trials in
Children Aged 1
Month to 11 Years
Old (2005,
Pritchard, et al).
Letter To The
Editor (2005,
Puntis, J. W. L.)

Editorial
comment/
expert
opinion

Theme/Treatment

Outcomes

Table I

Level of
Research
/Grade
Level
II/Grade
B

Study strengths/
Weaknesses
Non randomized
trial. Small
sample size.
Conservative
therapy can be
initiated without
side effects to
patients.

Recommend
for use
in review
Yes
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Article
Title/Author

Type of
Article/Study

Participants

Theme/Treatment

Outcomes

Level of
Research
/Grade
Level
VI/Grade
D

Stop the PPI
Express: They
Don’t Keep Babies
Quiet! (2009,
Putnam, P. E.)

Editorial
comment/
expert
opinion

Babies

Treatment with proton
pump inhibitors and
their affect on
gastroesophageal
reflux.

No outcomes noted.

No
recommendation
for use.

Commentary
(2005, Ravazzolo,
C. J.)

Editorial
comment/
Expert
opinion

Infants

Treatments for
gastroesophageal
reflux.

No outcomes noted.

Level
VI/Grade
D

No
recommendation
for use.

No.

Commentary
(2008, Savino &
Castagno)

Editorial
comment/
Expert
opinion

Infants

The use of thickened
formulas for the
treatment of
gastroesophageal
reflux.

No outcomes noted.

Level
VI/Grade
D

No
recommendation
for use.

No.

Overprescription of
Antireflux
Medications for
Infants With
Regurgitation
(2008, Savino &
Castagno)
Pediatric
Gastroesophageal
Reflux Disease
Case Study (2009,
Smith, et al)

Editorial
comment/
Expert
opinion

Infants

Use of antireflux
medications for infants
with regurgitation.

No outcomes noted.

Level
VI/Grade
D

No
recommendation
for use.

No.

Case study

Infant

Case study showing
manifestations of
GERD in an infant
beginning at 7 months
of age.

Outcome of the combination of
pharmacotherapy with
Lansoprazole, nutritional
supplementation, and behavioral
therapy were successful in treating
GERD.

Level
VI/Grade
D

No
recommendation
for use.

No

Table I

Study strengths/
Weaknesses

Recommend
for use
in review
No.
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Article
Title/Author

Type of
Article/Study

Participants

Theme/Treatment

Outcomes

Non
pharmacologic
Therapy May Be
Effective For
Infants With
Gastroesophageal
Reflux (2008,
Sondheimer, J.)
Safety and
Pharmacodynamics
of Lansoprazole in
Patients with
Gastroesophageal
Reflux Disease
Aged < 1 Year
(2008, Springer, et
al).

Editorial
Comment/ex
pert opinion

Infants

Conservative therapy in
the treatment of GERD.

No outcomes noted.

Single and
repeated
dose,
randomized,
parallelgroup, openlabel,
multicenter
study

Infants less
than 1 year of
age.

Effect of lansoprazole
on the symptoms of
GERD.

Gastroesophageal
Reflux in Infancy
and Childhood
(2006, Suwandhi,
et al).

Review
Article

Infants and
Children

Review looking at
GERD and its
symptoms, diagnosis
and treatments.

Over 5 days of daily dose
administration, lansoprazole was
well tolerated in neonates and
infants. Lansoprazole increased the
percentage of time that intragastric
pH was above 3, 4, 5, and 6 over the
24 hour post-dose period on days 1
and 5 when compared to baseline.
A decrease in the frequency of
GERD symptoms was also observed
although the study was not designed
to assess clinical benefit in children
<1 year of age.
Treatment objectives are relief of
symptoms. Avoidance of certain
foods that exacerbate acid reflux,
lifestyle modifications, nutritional
changes including thickening of
feeds. Hypoallergenic formula is
supported in infants with recurrent
emesis. H2 receptor antagonists or
proton pump inhibitors would be
the next line of treatment.
Prokinetic drugs remain
controversial for treatment. Next
step surgical intervention.

Table I

Level of
Research
/Grade
Level
VI/Grade
D

Study strengths/
Weaknesses
No
recommendation
for use.

Recommend
for use
in review
No

Level
II/Grade
B

Good study
design. Small
sample size at 24
infants.

Yes

Level
I/Grade
B

Review article
focusing on
infants and
children.

Yes
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Article
Title/Author

Type of
Article/Study

Participants

Theme/Treatment

Outcomes

Effect of an Amino
Acid-based Milk –
Neocate – on
Gastro
oesophageal Reflux
in Infants Assessed
by Combined
Intraluminal
Impedance/pH
(2006, Thomson, et
al).
Histamine H2
Receptor
Antagonists and
Proton Pump
Inhibitors: Best
Options for Gastro
oesophageal Reflux
in Children (2010,
Tighe, M., et al).

Non
randomized
study with
patients as
their own
control.

Infants under
12 months of
age with
clinically
suggestive
symptoms of
GOR.

Treatment with
Neocate to impact
symptoms of GOR.

The trial revealed a symptomatic
improvement on Neocate but cannot
be attributed to any positive effect
on GOR. There was no observable
difference in any reflux parameter
as measured by two methods.

Review
article.

Children

Best pharmacotherapy
for the treatment of
GOR.

Conservative approaches can assist
in the treatment of GOR. H2
receptor antagonists decrease acid
secretion. Ranitidine, cimetidine
and famotidine have shown efficacy
superior to placebo for symptom
relief and oesophageal healing in
many clinical trials. Proton pump
inhibitors are considered the most
effective acid suppressant
medications. There is no data for
use in infants under the age of 6
months or on the long-term safety in
children. Prokinetic agents such as
Metoclopramide and Domperidone,
limited benefit. There is
insufficient evidence to recommend
erythromycin and Bethanechol in
children with GOR. Antacids work
in the short term. Gaviscon Infant,
can improve symptoms of GOR.
Sulcrafate may improve symptoms.

Table I

Level of
Research
/Grade
Level
III/Grade
B

Level
I/Grade
B

Study strengths/
Weaknesses
Non-randomized.
Very small
sample size of 11
infants.

Review focusing
on infants.

Recommend
for use
in review
Yes

Yes
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Article
Title/Author

Type of
Article/Study

Participants

Current
Pharmacological
Management of
Gastro-Esophageal
Reflux in Children
– An EvidenceBased Systematic
Review (2009,
Tighe, et al).

Systematic
Review

Children

Theme/Treatment

Outcomes

Table I
Pharmacologic
management of
gastroesophageal
reflux.

Gaviscon Infant acts as a feed
thickener and prevents reflux by
increasing the viscosity of feeds.
Should be used with caution in
children at risk for dehydration.
Some evidence that it is effective.
There is insufficient evidence to
make a recommendation regarding
the role of antacids in children with
GERD. Oral Ranitidine provides
symptomatic relief and endoscopic
improvement of esophagitis in
children with GER. If the initial
dose of ranitidine fails to relieve
symptoms, a higher dose of
ranitidine or a proton-pump
inhibitor should be tried. There is
evidence to support the efficacy of
cimetidine in children with GERD
but there are significant adverse
effects. Omeprazole is effective in
improvement of symptoms, pH
probe findings and endoscopic
findings with a good tolerability and
safety profile. Omeprazole should
be the first-line treatment in severe
esophagitis in children. It is dosedependent. Less data available for
lansoprazole but it appears to be
effective in children. Lansoprazole
is dose dependent. Pantoprazole
appears to be effective with limited
data. Esomeprazole also has limited
data but appears to be effective.
There is limited efficacy of
metoclopramide in children with

Level of
Research
/Grade
Level
I/Grade
A

Study strengths/
Weaknesses
Systematic
review.

Recommend
for use
in review
Yes
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GER and significant adverse
effects.
There is little evidence of
Table I
benefit from Domperidone but there
are also no serious side effects
noted. There is currently not
enough evidence to draw
conclusions on the use of
erythromycin. No evidence exists
to suggest efficacy of bethanechol
in reducing GER in children.
Further evidence is needed to assess
the clinical benefit of sucralfate in
GERD.

43
Article
Title/Author

Type of
Article/Study

Participants

Controversies in
the Treatment of
Gastroesophageal
Reflux Disease in
Preterm Infants
(2009, Tipnis &
Tipnis).

Review
Article

Preterm Infants

Theme/Treatment
Table I
Review of varies
treatments used in the
treatment of GERD

Outcomes

Positioning: sitting exacerbates
GER. Faster gastric emptying can
be seen with less liquid reflux and
feeding on right side followed by
change to left side after 1 hour.
Thickening of feeds reduces number
and height of non acid reflux
episodes but does not decrease acid
reflux events. Continuous drip
feeding reduces vomiting and reflux
symptoms but chronic use of
indwelling tubes that cross the
gastroesophageal junction is
associated with increased
regurgitation and esophagitis. Oral
antacids and surface agents such as
alginates have been poorly studied
in preterm infants. Chronic antacid
use in preterm infants is not
recommended. Prokinetic agents
have limited role in the treatment of
GERD because there is a lack of
efficacy shown in the preterm
population. The efficacy of
bethanechol has not been
determined. Erythromycin has had
mixed results in improving reflux
scores and feeding tolerance in
preterm infants. Baclofen reduced
the frequency of transient lower
esophageal sphincter relaxation,
decreased acid reflux, and
accelerated gastric emptying in a
placebo-controlled study in infants.
There have been neurologic side

Level of
Research
/Grade
Level
I/Grade
B

Study strengths/
Weaknesses
Review article,
few studies
involving preterm
infants.

Recommend
for use
in review
Yes
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effects in adults. Ranitidine has
Table I been shown to protect against
steroid-induced ulcers in patients
who have chronic lung disease, in
the preterm population. Famotidine
reduced the frequency of
regurgitation and at a larger dose
reduced crying time in preterm
infants; the pharmacokinetics and
efficacy have not been studied in
preterm infants. The
pharmacokinetic and
pharmacodynamic properties of
lansoprazole and omeprazole have
been studied in a very small number
of neonates. Omeprazole
normalized the reflux index in a
small number of infants and
reduced the percentage of time
where the intragastric pH was less
than 4 but found no difference in
the frequency of reflux symptoms in
the placebo and omeprazole arms at
the end of treatment. An increased
risk of necrotizing enterocolitis as
found with chronic acid
suppression. In another study, acid
suppression with either H2RAs or
proton pump inhibitors was
associated with an increased
incidence of acute gastroenteritis
and community-acquired
pneumonia. There are various
surgical interventions that will not
be addressed in this review.

45
Article
Title/Author

Type of
Article/Study

Participants

Theme/Treatment

Outcomes

Multicenter,
Randomized,
Double-Blind
Study Comparing
10, 20, and 40 mg
Pantoprazole in
Children (5-11
Years) with
Symptomatic
Gastroesophageal
Reflux Disease
(2006, Tolia, et al).
Effect of Body
Position Changes
on Postprandial
Gastroesophageal
Reflux and Gastric
Emptying in the
Healthy Premature
Neonate (2007,
Van Wijk, et al).

Randomized,
double-blind,
parallel
group study.

Children aged
5 to 11 years
with confirmed
symptomatic
GERD.

Treatment with
Pantoprazole for
symptom relief in
GERD.

Pantoprazole (20 and 40 mg) is
effective in reducing endoscopically
proven GERD symptoms in
children. Both dosages
significantly reduced symptoms as
early as 1 week.

Randomized,
cross over
trial.

Healthy
preterm infants,
without
symptoms
related to
GERD.

Effect of position on
symptoms related to
GERD, left side to right
side and conversely,
right side to left side.

Right lateral positioning for the first
postprandial hour with a position
change to the left thereafter
promotes gastric emptying and
reduces liquid gastroesophageal
reflux in the late postprandial
period.

Table I

Level of
Research
/Grade
Level
II/Grade
B

Level
II/Grade
B

Study strengths/
Weaknesses
Good study
design. Small
sample size of 53
patients. Did not
specifically
address infants or
neonates.

Very small
sample size but
does show
promise with
conservative
interventions.

Recommend
for use
in review
Yes/Limited

Yes
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Article
Title/Author

Type of
Article/Study

Participants

Theme/Treatment
Table I

Gastroesophageal
Reflux: Medical
Treatment (2005,
Vandenplas, Y.)

Review
Article

Children

Treatments for
gastroesophageal
reflux.

Thickened Infant
Formula Does
What It Has To
Do: Decrease
Regurgitation
(2009, Vandenplas,
Y).

Editorial
comment/
Expert
opinion

Infants

Use of thickening
agents in the treatment
of gastroesophageal
reflux disease.

Outcomes

Conservative therapies and
reassurance are the best first
approach. Prone position has
lowest incidence of GER; left
lateral position has intermediate
incidence of GER. The prone
position with head elevated 30
degrees has the lowest incidence of
GER. Cornstarch as a thickening
agent shows decreased esophageal
acid exposure time. Prokinetic
agents such as metoclopramide,
domperidone and cisapride have
limited efficacy. There is limited
data for efficacy of erythromycin.
There is no pediatric data for
prucalopride, clebopride, or
itopride. Baclofen has some limited
data to support its use. Experience
with antacids is limited in infants.
Ranitidine and Nizatidine are not
well studied in children.
Omeprazole and lansoprazole have
been best studied in children and are
efficacious. Long term use of
gastric acid inhibitors has been
linked to bacterial overgrowth.
No outcomes noted.

Level of
Research
/Grade
Level
I/Grade
B

Level
VI/Grade
D

Study strengths/
Weaknesses
Review article
focusing on
children. Not too
specific for
infants and
neonates.

No
recommendation
for use.

Recommend
for use
in review
Yes

No
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Article
Title/Author

Type of
Article/Study

Participants

A Preliminary
Report On the
Efficacy of the
Multicare AR-Bed
in 3-week-3
month-old Infants
On Regurgitation,
Associated
Symptoms and
Acid Reflux (2010,
Vandenplas, et al).

Prospective
evaluation in
an open
intervention
pilot study.

3-week to 3
month old
infants.

Theme/Treatment

Outcomes

Table I
Use of multicare AR
(anti-reflux) bed and its
effect on
gastroesophageal
reflux.

The 40 degree position of the
incline bed decreased regurgitation
in a statistically and clinically
significant way.

Level of
Research
/Grade
Level
III/Grade
B

Study strengths/
Weaknesses
Very small
sample size (30).
Non-randomized,
non controlled
trial. High “drop
out” rate due to
infants
discomfort in the
inclined position.

Recommend
for use
in review
Yes/Limited
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Article
Title/Author

Type of
Article/Study

Participants

The Diagnosis and
Management of
Gastro
oesophageal Reflux
in Infants (2005,
Vandenplas, et al).

Review
article.

Infants.

Theme/Treatment
Table I
Treatment options for
gastroesophageal
reflux.

Outcomes

Prone position has lowest incidence
of GER; left lateral position has
intermediate incidence of GER.
The prone position with head
elevated 30 degrees has the lowest
incidence of GER. The risk of
SIDS must be considered with
positioning. Reduction in food
volumes can decrease the number of
regurgitations. Lifestyle changes
can impact reflux. Cow’s milk
allergy may impact GORD,
consider non cow’s milk formula.
Cornstarch as a thickening agent
shows decreased esophageal acid
exposure time. Because of
nutritional concerns, commercially
thickened formula is preferred to
thickening agents added to formula.
Prokinetic agents such as
metoclopramide, domperidone and
cisapride have limited efficacy.
There is limited data for efficacy of
erythromycin. There is no or very
little pediatric data for ondansetron,
tegaserod, prucalopride, clebopride,
or itopride. Experience with
antacids is limited in infants.
Alginate-based, raft forming
formulations which, in the presence
of gastric acid, precipitates forming
a gel, and later a foam-like pH
neutral barrier in the stomach.
Aluminum containing antacids
should not be given to infants and

Level of
Research
/Grade
Level
I/Grade
B

Study strengths/
Weaknesses
Review article
with many older
articles.

Recommend
for use
in review
Yes

49
toddlers because of the nutritional
and neurotoxic side effects.
Table I
Sucralfate, which also contains
aluminum, should not be used in
infants. Ranitidine, famotidine, and
Nizatidine are not well studied in
children. Omeprazole and
lansoprazole have been best studied
in children and are efficacious.
Long term use of gastric acid
inhibitors has been linked to
bacterial overgrowth.

50
Article
Title/Author

Type of
Article/Study

Participants

Gastroesophageal
Reflux in Infancy,
A Common But
Challenging
Presentation (2008,
Weill, V).

Review
Article

Infants

Theme/Treatment
Table I
Treatment options for
gastroesophageal reflux
disease.

Outcomes

Uncomplicated GER in infants
requires time as it often resolves by
the first birthday. Conservative
therapy consisting of lifestyle and
behavioral management would be
the next line of defense. Small,
more frequent feedings with
frequent burping can help reduce
symptoms of GER. Cow’s milk
protein allergy may be the cause of
GER symptoms, trial of
hypoallergenic formula for
determination is recommended.
Prone positioning decreases reflux
but the risk of SIDS is of greater
concern. Supine positioning is still
recommended. A smoke-free
environment may be beneficial for
babies with reflux. Thickening
agents does not reduce the acid
reflux but regurgitation episodes.
The acid is still there, but it cannot
be seen in vomiting. Thickening of
feeds can be used to treat reflux.
Antacids are not recommended for
long-term use. Ranitidine,
famotidine, and Nizatidine are not
well studied in children.
Omeprazole and lansoprazole have
been best studied in children and are
efficacious. They are not approved
for use in infants.

Level of
Research
/Grade
Level
I/Grade
B

Study strengths/
Weaknesses

Yes

Recommend
for use
in review
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Article
Title/Author

Type of
Article/Study

Participants

Theme/Treatment

Cornstarch
Thickened Formula
Reduces
Oesophageal Acid
Exposure Time in
Infants (2005,
Xinias, et al).

Blinded,
randomized
controlled
trial.

Formula-fed
infants with a
mean age of 93
days.

Cornstarch thickened
formula and its effect
on gastroesophageal
reflux.

Age-Dependent
Pharmacokinetics
of Lansoprazole in
Neonates and
Infants (2008,
Zhang, et al).

Single and
repeated
dose,
randomized,
open-label,
multicenter
study.

20 neonates
(<28 days old)
and 20 infants
(>28 days but
<1 year old)

Treatment with
lansoprazole and the
age dependent dose
needed to treat
gastroesophageal
reflux.

Pharmacokinetic
Properties of
Esomeprazole in
Children Aged 1 to
11 Years with
Symptoms of
Gastroesophageal
Reflux Disease: A
Randomized,
Open-Label Study
(2006, Zhao, et al)

Randomized,
open label
study.
Uncontrolled.

Children 1 – 11
years old
stratified into
groups: 1-5
years and 6-11
years.

Effects of
Esomeprazole of
children in the
treatment of
gastroesophageal reflux
disease.

Outcomes

Level of
Research
/Grade

Study strengths/
Weaknesses

Recommend
for use
in review

A formula thickened with a
specifically treated cornstarch
reduces oesophageal acid exposure
and reduces the frequency of
clinical symptoms. In addition, the
group receiving the cornstarch
thickened formula had better weight
gain – possibly related to decreased
vomiting in part.
The pharmacokinetics of
lansoprazole are age dependent.
Pediatric patients aged < 10 weeks
require a lower dose of lansoprazole
than pediatric patients aged > 10
weeks to achieve similar plasma
exposure. Effectiveness of
lansoprazole in subjects < 1 year old
has not been established and was
not addressed in this study.
This study shows that the
pharmacokinetic properties of
esomeprazole in children aged 1 to
11 years who have GERD may be
both dose and age dependent. The
metabolism of esomeprazole per
kilogram of body weight is more
rapid in younger (aged 1-5 years)
children than in older (aged 6-11
years) children. Doses were well
tolerated. This study did not
address the effectiveness of
esomeprazole.

Level
II/Grade
B

Randomized
controlled trial
with relatively
large sample size.

Yes

Level
II/Grade
B

Good study
design, small
sample size.

Yes

Level
II/Grade
B

Randomized trial
without control.
Small sample
size of 31
children.

Yes

Table I
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Chapter 4: Conclusions
Gastroesophageal reflux disease (GERD) is often assumed in the neonatal and infant
population due to feeding intolerance and behavioral manifestations. To this day, there is no
generally-agreed-upon test to determine if an infant is suffering from GERD. Unfortunately,
even without diagnosis, GERD is treated frequently, especially in the hospital setting. There are
not often practice guidelines for the treatment of GERD in the infant population. At the very
least, it would be important to start with conservative treatments before moving towards diet
changes and medications, as the evidence supports.
The majority of the articles and studies included in this systematic review focused on
neonates and infants, except those studies looking at medications. There were relatively few
well designed studies focusing on currently prescribed medications in the neonatal and infant
populations. This can cause inappropriate dosing and perhaps prescribing of medications that are
not well tolerated in infants if not well studied.
There were many studies that identified some interventions not to be efficacious. This is
valuable information as it eliminates useless treatments from an approach to care. In addition,
some medications that have been studied are not effective or may actually be harmful, such as
cisapride.
Best Practice for the Treatment of Gastroesophageal Reflux
There are evidence-based best practices for the treatment of gastroesophageal reflux
disease. Initially, conservative therapies should be attempted as their side effects are minimal.
Parental reassurance and education had significant results related to reducing the symptoms of
gastroesophageal reflux. Symptoms of reflux diminish and even disappear over time, supporting
this intervention (Orenstein & McGowan, 2008). If further treatment is warranted, there is
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evidence that prone or left lateral positioning increases gastric emptying time and, therefore,
decreases gastroesophageal reflux events. This positioning must be used with caution because of
the risk of Sudden Infant Death Syndrome (SIDS). Cardiac monitoring must be used in
conjunction with prone or left side positioning; therefore, in most cases, this intervention cannot
be recommended for use in the hospital setting. One randomized crossover trial by Van Wijk, et
al, (2007), showed that a right lateral position for the first hour following a feeding with a change
to the left thereafter promoted gastric emptying. This had a very small sample size, but, with
cardiac monitoring, could be used to decrease symptoms.
Feeding interventions can also be useful in the treatment of gastroesophageal reflux
disease (GERD) and are still considered to be conservative. Smaller, more frequent feedings can
decrease the symptoms of GERD. In addition, thickening of feedings can also decrease reflux
episodes.
If these conservative therapies are not successful in treating GERD, there are some
medications that have proven to be successful in either their acid suppression effects or their
ability to increase gastric emptying times. It is important, especially with the use of
pharmaceuticals, to monitor the effects of the medications and determine the continuing need for
intervention.
Recommendations for Future Research
More research in the diagnosis of gastroesophageal reflux should be done so that
treatment without diagnosis can be avoided. There is not a generally agreed upon “gold
standard” to determine the presence of GERD. The diagnosis of GERD is made based upon
symptoms such as vomiting, arching, crying, and irritability. These are vague symptoms that
may be explained by another diagnosis. In addition, having an infant with GERD or suspected
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GERD is stressful for families and may be expensive. It will be important in the future with
stricter controls on healthcare dollars to determine true cases of GERD and treat them
appropriately and to avoid treatment when GERD is not present.
Recommended approach to the treatment of GERD
The following is a listing of treatments from conservative to pharmacotherapy that can be
used in the treatment of GERD in a stepped approach:


Parental reassurance should be used as a first treatment as it is the easiest, least invasive
treatment for infant regurgitation as symptoms usually decrease and disappear over time
(Grade B).



Prone or left-lateral positioning after feedings can reduce GERD in preterm infants but
cannot be used without cardiac monitoring because of the risk of SIDS; if this is to be
used as an early intervention, the patient must be continuously monitored and this must
be discontinued prior to discharge home (Grade B).



Faster gastric emptying can be seen with less liquid reflux and feeding on right side
followed by change to left side after 1 hour. This approach must also include cardiac
monitoring because of the risk of SIDS (Grade B).



Small, slow, and more frequent feedings (with frequent burping) in a relaxed
environment are helpful to infants with delayed gastric emptying (Grade B).



Eliminating exposure to cow’s milk (Grade B).



Thickened feedings utilizing a commercially available product such as Enfamil AR
because of the balanced nutrition in commercial products (Grade B).



Cereal thickened formula (rice or oatmeal) can be used to reduce the frequency of
regurgitation (Grade B).
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Cornstarch can be used to thicken formula if commercially available products or cereal
for thickening are unsuccessful (Grade B).



Hypoallergenic formula is supported in infants with recurrent emesis (Grade B).



Gaviscon Infant can be used as it increases the viscosity of feeds and reduces reflux
(Grade B).



Ranitidine can be used as a first line medication treatment (Grade B).



Omeprazole can be limitedly recommended in children under 2 years, but it is better
studied in older children (Grade B).



Lansoprazole is well tolerated in neonates and infants but its efficacy is only established
in children older than 1 year (Grade B).



Esomeprazole does have acid suppressive effects in infants older than 1 month at a dose
of 1mg/kg; systemic exposure in preterm infants and neonates at a dose of 0.5mg/kg
showed acid suppression but no effect on actual reflux events. Esomeprazole is only
approved for use in children older than 1 year (Grade B).



Cimetidine can be recommended limitedly for reduced regurgitation; it is not
recommended for preterm infants (Grade B).

Limitations to the Study
The main limitations to this study were the ability to correlate the available studies on
drug therapies done on adults to the neonatal and infant populations. Very few studies on
pharmacologic agents and their efficacy in the neonatal/infant population have been
completed although their use is widespread (Orenstein & Hassall, 2007). Not all review
articles or studies were limited to the target population or the inclusion criteria of children up
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to five years of age. It was difficult in some instances to extrapolate data for the target
population.
Articles reviewed for this study demonstrated varied designs and methodologies. In
many of the studies and articles reviewed, there were small sample sizes. Despite limitations
to some of the studies and review articles, there are core themes that can be applied to the
target population of neonates and infants.
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